| Literature DB >> 33921760 |
Angelica Petrillo1,2, Emilio Francesco Giunta1,2, Annalisa Pappalardo1,2, Davide Bosso1, Laura Attademo1, Cinzia Cardalesi1, Anna Diana1,2, Antonietta Fabbrocini1, Teresa Fabozzi1, Pasqualina Giordano1, Margaret Ottaviano1,3,4, Mario Rosanova1, Antonia Silvestri1, Piera Federico1, Bruno Daniele1.
Abstract
Gastric cancer (GC) is the third cause of cancer-related death worldwide; the prognosis is poor especially in the case of metastatic disease. Liver, lymph nodes, peritoneum, and lung are the most frequent sites of metastases from GC; however, bone metastases from GC have been reported in the literature. Nevertheless, it is unclear how the metastatic sites may affect the prognosis. In particular, knowledge about the impact of bone metastases on GC patients' outcome is scant, and this may be related to the rarity of bone lesions and/or their underestimation at the time of diagnosis. In fact, there is still a lack of specific recommendation for their detection at the diagnosis. Then, the majority of the evidences in this field came from retrospective analysis on very heterogeneous study populations. In this context, the aim of this narrative review is to delineate an overview about the evidences existing about bone metastases in GC patients, focusing on their incidence and biology, the prognostic role of bone involvement, and their possible implication in the treatment choice.Entities:
Keywords: RANK-L; bone flare; metastatic gastric cancer; stage IV; target therapy; treatment
Year: 2021 PMID: 33921760 DOI: 10.3390/jcm10081777
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241